Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Arnon P. Kater; Sanne H. Tonino; Marjolein Spiering; Martine E. D. Chamuleau; Roberto Liu; Adeboye Henry Adewoye; Jie Gao; Lyndah Dreiling; Yan Xin; Jeanette K. Doorduijn; Marie José Kersten

doi:10.1038/s41408-018-0055-x

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Arnon P. Kater, Sanne H. Tonino, Marjolein Spiering, Martine E. D. Chamuleau, Roberto Liu, Adeboye Henry Adewoye, Jie Gao, Lyndah Dreiling, Yan Xin, Jeanette K. Doorduijn, Marie José Kersten

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Original language	English
Article number	16
Journal	Blood cancer journal
Volume	8
Issue number	2
DOIs	https://doi.org/10.1038/s41408-018-0055-x
Publication status	Published - 2018

Access to Document

10.1038/s41408-018-0055-x

Cite this

Kater, A. P., Tonino, S. H., Spiering, M., Chamuleau, M. E. D., Liu, R., Adewoye, A. H., Gao, J., Dreiling, L., Xin, Y., Doorduijn, J. K., & Kersten, M. J. (2018). Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies. Blood cancer journal, 8(2), [16]. https://doi.org/10.1038/s41408-018-0055-x

@article{842f23cfc9eb4bdf8677a0c9ff5d2062,

title = "Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies",

author = "Kater, {Arnon P.} and Tonino, {Sanne H.} and Marjolein Spiering and Chamuleau, {Martine E. D.} and Roberto Liu and Adewoye, {Adeboye Henry} and Jie Gao and Lyndah Dreiling and Yan Xin and Doorduijn, {Jeanette K.} and Kersten, {Marie Jos{\'e}}",

year = "2018",

doi = "10.1038/s41408-018-0055-x",

language = "English",

volume = "8",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "2",

}

Kater, AP, Tonino, SH, Spiering, M, Chamuleau, MED, Liu, R, Adewoye, AH, Gao, J, Dreiling, L, Xin, Y, Doorduijn, JK & Kersten, MJ 2018, 'Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies', Blood cancer journal, vol. 8, no. 2, 16. https://doi.org/10.1038/s41408-018-0055-x

TY - JOUR

T1 - Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

AU - Kater, Arnon P.

AU - Tonino, Sanne H.

AU - Spiering, Marjolein

AU - Chamuleau, Martine E. D.

AU - Liu, Roberto

AU - Adewoye, Adeboye Henry

AU - Gao, Jie

AU - Dreiling, Lyndah

AU - Xin, Yan

AU - Doorduijn, Jeanette K.

AU - Kersten, Marie José

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042012706&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29434192

U2 - 10.1038/s41408-018-0055-x

DO - 10.1038/s41408-018-0055-x

M3 - Comment/Letter to the editor

C2 - 29434192

SN - 2044-5385

VL - 8

JO - Blood cancer journal

JF - Blood cancer journal

IS - 2

M1 - 16

ER -

Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies

Access to Document

Other files and links

Cite this